2 results
Not approvedWill not start
The purpose of this study is the evaluation of InPen* with InPen* 2.0 app and Guardian* 4 system in adult patients with type 1 diabetes for the design of a future study.
Approved WMOWill not start
Primary ObjectiveSafety Lead-in* Evaluate the safety of a high-dose regimen of encorafenib + binimetinib combination therapy in patients with BRAFV600-mutant melanoma who have asymptomatic brain metastasisPhase 2If the high-dose regimen is…